SWSaiying Wang

Saiying Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Saiying Wang has a total of 229 co-authors. Here are the top co-authors by number of shared publications:

  • Kaiming Duan

    Department of Anesthesiology, The Third Xiangya Hospital of Central South University, Changsha, China

    7 shared publications
  • Kai-Ming Duan

    Department of Anesthesiology, The Third Xiangya Hospital of Central South University, Changsha, China

    6 shared publications
  • Qiuwen Li

    Cent South Univ, Xiangya Hosp 3, Yinpenling St, Changsha 410013, Hunan, Peoples R China

    6 shared publications
  • Kai Gao

    Cent South Univ, Dept Anesthesiol, Xiangya Hosp 3, Changsha 410013, Peoples R China

    5 shared publications
  • Shouyu Xu

    Cent South Univ, Xiangya Hosp 3, Yinpenling St, Changsha 410013, Hunan, Peoples R China

    5 shared publications
  • Chun Chen

    Department of Anesthesiology, Yichang Central People’s Hospital, Yichang, China

    4 shared publications

Latest Publications

  • Open Access

    Intravenous aprepitant for prevention of postoperative nausea and vomiting in adults at moderate-to-high risk in China: a multicenter, randomized, double-blind, placebo-controlled trial

    by Shichao Luo, Xiangqin Teng, YingYong Zhou, Qinghong Mao, Qingmei Zhang, Hong Luo, Liang Chen, Juan Wang, Hongmei Zhou, Jun Jing, et al.

    Purpose: To evaluate whether peri-induction intravenous aprepitant 32mg/4.4ml improves the complete response (CR) to postoperative nausea and vomiting (PONV) within 24 h after surgery, as well as the 0–48 h net clinical effect, safety, and pharmacokinetic outcomes, in Chinese adults at moderate to high risk of PONV under a standardized rescue protocol. Methods: This multicenter, randomized, double-blind, placebo-controlled clinical trial was conducted in 30 hospitals in China. A total of 412 patients scheduled for abdominal or pelvic surgery with an Apfel simplified risk score ≥ 2 were randomized 1:1 to the aprepitant group ( n = 206) or placebo ( n = 206). Patients in the aprepitant group received intravenous aprepitant 32 mg before anesthesia induction, while those in the control group received placebo. Rescue antiemetics were administered only for clinically significant postoperative symptoms. The primary endpoint was CR within 24 h after surgery, defined as no vomiting or retching and no use of rescue antiemetic therapy during the first 24 postoperative hours. Secondary endpoints included time to first emesis within 48 h, incidence of moderate-to-severe nausea within 24 h, and rescue antiemetic use within 24 h after surgery. A pharmacokinetic substudy ( n = 28) measured plasma aprepitant concentration at 0 and 2 min, 5 min, 15 min, 1 h, 3 h, 6 h, 24 h and 48 h after completion of administration. Adverse events were recorded to assess safety. Results: Aprepitant significantly increased the rate of CR within 24 h compared with placebo (81.4% vs. 39.0%; P < 0.001). Vomiting within 48 h occurred less frequently in the aprepitant group than in the control group (16.7% vs. 62.0%; P < 0.001), and time to first emesis within 48 h was significantly delayed with aprepitant (log-rank P < 0.001). The proportion of patients with no emesis was higher in the aprepitant group at both 24 h (84.8% vs. 40.0%; weighted risk difference, 45.07% [95% CI, 36.90%–53.24%]) and 48 h (83.3% vs. 38.0%; weighted risk difference, 45.55% [95% CI, 37.29%–53.81%]). Moderate-to-severe nausea within 24 h was reduced with aprepitant (16.7% vs. 33.2%; P < 0.001), as was rescue antiemetic use within 24 h (8.3% vs. 22.0%; P < 0.001). In the pharmacokinetic substudy, the mean (SD) C max was 4997.95 (1226.44) ng/mL, the median (range) T max was 0.035 (0.031–0.076), and the mean (SD) half-life ( T 1/2 ) was 9.08 (2.17). Adverse reaction profiles were similar between groups. Conclusions: Peri-induction intravenous aprepitant 32 mg substantially improved the 24 h CR rate in Chinese adults at moderate to high risk of PONV undergoing abdominal or pelvic surgery. This benefit was accompanied by delayed time to first emesis, reduced moderate-to-severe nausea, and lower rescue antiemetic use, with a safety profile comparable to placebo. Clinical trial registration: Chinese Clinical Trial Registry, ChiCTR2400082488. Registered on 29 March 2024, https://www.chictr.org.cn/showproj.html?proj=224587 .

  • Open Access

    NH600001, an etomidate analogue, provides gastrointestinal endoscopy sedation/anesthesia and reduces adrenocortical depression: two randomized controlled trials

    by Yingyong Zhou, Kaiming Duan, Shichao Luo, Shengping Liu, Qiongcan Li, Songhua Liu, Huajing Guo, Haitao Jiang, Guyan Wang, Huijun Wang, et al.

    To evaluate the efficacy and safety of NH600001, a novel etomidate derivative, in gastrointestinal endoscopy, as well as its impact on adrenocortical function, two multicenter, double-blind, randomized, controlled clinical trials(NH600001-21 [Phase II trial] and NH600001-31 [Phase III trial]) were conducted in China. In NH600001-21, 160 gastroscopy subjects were randomized 1:1:1:1 to receive NH600001 (0.20, 0.25, or 0.30 mg/kg) and etomidate (0.30 mg/kg). In NH600001-31, 344 gastroscopy or colonoscopy subjects were randomized in a 1:1 ratio to receive NH600001 (0.25 mg/kg) and etomidate (0.30 mg/kg). The primary efficacy outcome was the rate of endoscopic success. Additionally, Safety and effects on adrenocortical function were also assessed. In NH600001-21, the 0.25 mg/kg NH600001 showed non-inferiority to etomidate based on the prespecified non-inferiority margin of −8% (Rate Difference [95% confidence interval], 5.0[−4.49 to 14.49]), whereas the 0.20 mg/kg and 0.30 mg/kg NH600001 did not meet statistical non-inferiority criteria (0[−11.54 to 11.54]; 0[−11.54 to 11.54]). The area under curve (AUC) of plasma cortisol change values within 0-4 h (∆Cortisol AUC0-4h) were significantly higher in the NH600001 treatment groups than in the etomidate group (P < 0.01). In NH600001-31, NH600001 (0.25 mg/kg) showed non-inferiority to etomidate (1.16[−0.44 to 2.76]). ∆Cortisol AUC0-4h in the NH600001 group, versus the etomidate group, were significantly higher (P < 0.001). Furthermore, NH600001 had a safety profile comparable to etomidate and elicited fewer myoclonus adverse events. In Conclusions, NH600001 has a sedative/anesthetic effect comparable to etomidate while reducing the risk of adrenocortical depression with a favorable safety profile. Chictr.org.cn identifier: ChiCTR2300069841, ChiCTR2400084095. Clinical Trial Number and Registry URL: NH60001-21, Identifier, ChiCTR2300069841 (Changsha, China;, principal investigator: Wen Ouyang, first registration date: March 28, 2023), https://www.chictr.org.cn; NH60001-31, Identifier, ChiCTR2400084095 (Changsha, China, principal investigator: Wen Ouyang, first registration date: May 10, 2024), https://www.chictr.org.cn.


  • Decoding the molecular network communication mechanism of ketamine’s antidepressant effects

    by Ye Li, Qilong Cheng, Guoxin Lin, Kaiming Duan, Saiying Wang

  • Open Access

    Efficacy and safety of HR020602 in combination with propofol in children receiving general anesthesia: a multicenter, phase 2 study

    by Nan Zou, Xiaoling Wang, Fang Wang, Xiaohua Zou, Sai-Ying Wang, Wangning Shangguan, Xuemei Lin, Qian Lei, Yonghao Yu, Zhiping Wang, et al.

    The objective of this study was to evaluate the efficacy and safety of esketamine hydrochloride injection (HR020602) in combination with propofol for the i

  • Open Access

    Safety, tolerability, and pharmacokinetics of 4-fluoroetomidate (NH600001) in healthy subjects: a first-in-human, randomised, controlled, phase I study

    by Yuanyuan Sun, Jie Huang, Kaiming Duan, Yaqi Lin, Qian Wu, Jinlian Xie, Can Guo, Yajie Cao, Ling Ye, Shuang Yang, et al.


  • Open Access

    Efficacy and safety of 4‐hydroxy 2‐methyl‐N‐(5‐methyl‐2‐thiazolyl)‐2H‐1, 2‐benzothiazin‐3‐carboxamide 1,1‐dioxide, a fast‐acting meloxicam formulation, on moderate‐to‐severe pain following abdominal surgery: A phase III randomized controlled trial

    by Xiaohua Liu, Yanhua Zhao, Mengchang Yang, Jinghua Ren, Wen Ouyang, Saiying Wang, Yufei Shen, Yuanli Gao, Ling Zhao, Zhong Qin, et al.

    4‐hydroxy 2‐methyl‐N‐(5‐methyl‐2‐thiazolyl)‐2H‐1, 2‐benzothiazin‐3‐carboxamide 1,1‐dioxide (QP001), a novel long‐lasting meloxicam formulation, may provide adequate postoperative pain relief with a good safety profile. This study aimed to evaluate the efficacy and safety of QP001 for moderate‐to‐severe pain following abdominal surgery. This multicenter, randomized, double‐blind, placebo‐controlled phase III trial recruited patients undergoing abdominal surgery at 23 centers between October 30, 2022, and July 10, 2023. Patients were randomized to a QP001 or placebo group in a 2:1 ratio. Postoperative pain intensity was evaluated using the Numerical Rating Scale. The primary efficacy outcome was the area under curve (AUC) of pain intensity‐time 0–24 h after awakening from anesthesia (AUC0–24). Adverse events and drug reactions were recorded to evaluate safety. A total of 258 patients underwent randomization, and 255 patients received at least one trial drug, including 170 in the QP001 group and 85 in the placebo group. Among these patients, 250 completed the study. The AUC0–24 was significantly lower in the QP001 group than in the placebo group (50.5 vs. 85.19, difference of 34.69 [40.7%], p < 0.0001). This was accompanied by a decrease in morphine use and an increase in patient satisfaction. Moreover, the overall adverse events or adverse drug reaction rates were similar between the QP001 and placebo groups. Among patients undergoing abdominal surgery, postoperative pain was significantly lower in the QP001 group than in the placebo group. QP001 has a great analgesic effect of up to 24 h and satisfactory safety in patients with moderate‐to‐severe abdominal pain.


  • Efficacy and safety of 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1, 2-benzothiazin-3-carboxamide 1,1-dioxide, a rapid-acting meloxicam formulation, for analgesia after orthopaedic surgery under general anaesthesia: a randomized controlled trial

    by Yingyong Zhou, Yan Jiang, Kaiming Duan, Qiongcan Li, Mengchang Yang, Qing Lei, Mingsheng Bao, Guijie Xie, Jie Sun, Liang Chen, et al.

    Background Postoperative pain management is one of the most challenging treatments after orthopaedic surgery, and improved medical treatment options are urgently needed. This study aimed to evaluate the efficacy and safety of 4-hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1, 2-benzothiazin-3-carboxamide 1,1-dioxide (QP001) for moderate to severe pain following orthopaedic surgery. Methods This randomized clinical trial enlisted patients experiencing moderate to severe pain following orthopaedic surgery in 20 hospitals in China. We allocated randomly 132 participants to receive 30 mg QP001 and 66 participants to receive 0.9% saline pre-surgery. The primary efficacy outcome was the total morphine consumption within 24 h. Results The total morphine consumption in the QP001 group, versus placebo group, was significantly lower over the following 24 h [12.53 (10.51) vs. 26.13 (13.98), P < 0.001]. The total morphine consumption in the QP001 group, versus placebo group, was also significantly decreased over the following 48 h (P < 0.001). The QP001 group, versus placebo, showed a significant decrease in the effective pressing times of the analgesic pump, morphine relief analgesia ratio over the 24 h and 48 h periods and the area under the curve for pain intensity-time as well as a significant prolonged in the time of first pressing the analgesic pump and the time of first morphine rescue analgesia (P < 0.001). The QP001 groups, versus placebo, show no significant difference in adverse events, but the incidence of adverse drug reactions decreased (59.4% vs. 75.8%, P = 0.023). Conclusion QP001 provides analgesia and reduces opioid consumption in patients with moderate to severe pain after orthopaedic surgery, with a favorable safety profile.


  • Open Access

    Effect of Dexmedetomidine on Postpartum Depression in Women With Prenatal Depression

    by Yingyong Zhou, Zhihong Bai, Wenchao Zhang, Shouyu Xu, Yunfei Feng, Qiuwen Li, Lishan Li, Anqi Ping, Liang Chen, Saiying Wang, et al.

    Importance: Postpartum depression (PPD) is emerging as a major public health problem worldwide. Although the particular period and context in which PPD occurs provides an opportunity for preventive interventions, there is still a lack of pharmacologic prevention strategies for PPD.Objective: To assess the efficacy and safety of dexmedetomidine for prevention of PPD among women with prenatal depression undergoing cesarean delivery.Design, Setting, and Participants: This randomized clinical trial enrolled 338 women who screened positive for prenatal depression at 2 hospitals in Hunan, China from March 28, 2022, to April 16, 2023. Women with an Edinburgh Postnatal Depression Scale score of more than 9 who were 18 years of age or older and were scheduled for elective cesarean delivery were eligible.Interventions: Eligible participants were randomly assigned in a 1:1 ratio to either the dexmedetomidine group or the control group via centrally computer-generated group randomization. Dexmedetomidine, 0.5 μg/kg and 0.9% saline were intravenously infused for 10 minutes after delivery in the dexmedetomidine and control groups, respectively. After infusion, sufentanil or dexmedetomidine plus sufentanil was administered via patient-controlled intravenous analgesia for 48 hours in the control group and dexmedetomidine group, respectively.Main Outcomes and Measures: The primary outcome was positive PPD screening results at 7 and 42 days post partum, defined as a postpartum Edinburgh Postnatal Depression Scale score of more than 9. Analysis was on an intention-to-treat basis.Results: All 338 participants were female, with a mean (SD) age of 31.5 (4.1) years. Positive PPD screening incidence at 7 and 42 days post partum in the dexmedetomidine group vs the control group was significantly decreased (day 7, 21 of 167 [12.6%] vs 53 of 165 [32.1%]; risk ratio, 0.39 [95% CI, 0.25-0.62]; P < .001; day 42, 19 of 167 [11.4%] vs 50 of 165 [30.3%]; risk ratio, 0.38 [95% CI, 0.23-0.61]; P < .001). The dexmedetomidine group showed no significant difference in adverse events vs the control group (46 of 169 [27.2%] vs 33 of 169 [19.5%]; P = .10), but the incidence of hypotension increased (31 of 169 [18.3%] vs 16 of 169 [9.5%]; risk ratio, 2.15 [95% CI, 1.13-4.10]; P = .02).Conclusions and Relevance: Dexmedetomidine administration in the early postpartum period significantly reduced the incidence of a positive PPD screening and maintained a favorable safety profile.Trial Registration: Chinese Clinical Trial Registry Identifier: ChiCTR2200057213


  • Preemptive QP001, a fast-acting meloxicam formulation, provides analgesia and reduces opioid consumption following abdominal surgery: a randomized controlled trial

    by Yingyong Zhou, Bin Wang, Kaiming Duan, Zhihong Bai, Xianwen Hu, Mingjun Xu, Xiaohong Li, Yuanli Gao, Jiangang Li, Mengchang Yang, et al.

    Background QP001, a novel meloxicam formulation, has been developed to manage moderate to severe postoperative pain. This study aimed to evaluate the efficacy and safety of QP001 injections for moderate to severe pain following abdominal surgery. Method This prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial enlisted patients experiencing moderate to severe pain following abdominal surgery. These patients were randomized to receive either QP001 injections (30 mg or 60 mg) or a placebo pre-surgery. The primary efficacy endpoint was the total morphine consumption within 24 h after the first administration. Results A total of 108 patients were enrolled, and 106 patients completed the study. The total morphine consumption in the QP001 30 mg group and 60 mg group, versus placebo group, were significantly lower over the following 24 h (5.11[5.46] vs 8.86[7.67], P = 0.011; 3.11[3.08] vs 8.86[7.67], P < 0.001), respectively. The total morphine consumption in the QP001 30 mg and 60 mg groups, versus placebo group, was also significantly decreased over the following 48 h, including the 24–48 h period (P ≤ 0.001). The QP001 30 mg and 60 mg groups, versus placebo, showed a significant decrease in the area under the curve for pain intensity-time as well as a significant decrease in the effective pressing times of the analgesic pump over the 24 h and 48 h periods (P < 0.05). The QP001 groups, versus placebo, show no significant different in Adverse Events or Adverse Drug Reactions (P > 0.05). Conclusion Preoperative/preemptive QP001 provides analgesia and reduces opioid consumption in patients with moderate to severe pain following abdominal surgery, while maintaining a favorable safety profile.